Showing results (161-170 of 469) with videos related to
Sort By:
Pageof 47
The Oncologist|February 16, 2018
A Curative-Intent Trimodality Approach for Isolated Abdominal Nodal Metastases in Metastatic Colorectal Cancer: Update of a Single-Institutional ExperienceBenny Johnson, Zhaohui Jin, Michael G Haddock, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 28, 2009
Improved survival in metastatic colorectal cancer is associated with adoption of hepatic resection and improved chemotherapyScott Kopetz, George J Chang, Michael J Overman, et al.Cancer Chemotherapy and Pharmacology|September 23, 2024
Phase I-II study of OBI-888, a humanized monoclonal IgG1 antibody against the tumor-associated carbohydrate antigen Globo H, in patients with advanced solid tumorsApostolia Maria Tsimberidou, Axel Grothey, Darren Sigal, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 20, 2008
Efficacy of oxaliplatin plus capecitabine or infusional fluorouracil/leucovorin in patients with metastatic colorectal cancer: a pooled analysis of randomized trialsHendrik-Tobias Arkenau, Dirk Arnold, Jim Cassidy, et al.Therapeutic Advances in Medical Oncology|March 24, 2020
Dual VEGF inhibition with sorafenib and bevacizumab as salvage therapy in metastatic colorectal cancer: results of the phase II North Central Cancer Treatment Group study N054C (Alliance)Hao Xie, Jacqueline M Lafky, Bruce W Morlan, et al.Breast Cancer Research : BCR|April 5, 2019
The lncRNA MIR2052HG regulates ERα levels and aromatase inhibitor resistance through LMTK3 by recruiting EGR1Junmei Cairns, James N Ingle, Krishna R Kalari, et al.Clinical Breast Cancer|January 18, 2016
Phase I Study of Panobinostat (LBH589) and Letrozole in Postmenopausal Metastatic Breast Cancer PatientsWinston W Tan, Jacob B Allred, Alvaro Moreno-Aspitia, et al.Journal of Cancer Research and Clinical Oncology|April 13, 2018
MODUL-a multicenter randomized clinical trial of biomarker-driven maintenance therapy following first-line standard induction treatment of metastatic colorectal cancer: an adaptable signal-seeking approachHans-Joachim Schmoll, Dirk Arnold, Aimery de Gramont, et al.Current Colorectal Cancer Reports|September 14, 2013
The IDEA (International Duration Evaluation of Adjuvant Chemotherapy) Collaboration: Prospective Combined Analysis of Phase III Trials Investigating Duration of Adjuvant Therapy with the FOLFOX (FOLFOX4 or Modified FOLFOX6) or XELOX (3 versus 6 months) Regimen for Patients with Stage III Colon Cancer: Trial Design and Current StatusThierry André, Timothy Iveson, Roberto Labianca, et al.Clinical Colorectal Cancer|June 13, 2026
Prognostic Value of Liver Metastases and KRAS Mutations in Patients With Metastatic Colorectal Cancer: A Pooled Analysis of Third-Line Placebo-Controlled Trials From the ARCAD CRC DatabaseThomas Samaille, Morteza Raeisi, Romain Cohen, et al.Pageof 47